Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Treatment of vulvar and vaginal warts

Daniela A Carusi, MD, MSc
Section Editor
Robert L Barbieri, MD
Deputy Editor
Kristen Eckler, MD, FACOG


Vulvar and vaginal warts are one of the clinical manifestations of human papillomavirus (HPV) infection (picture 1A-C). Approximately 90 percent of anogenital warts are associated with HPV types 6 and/or 11, which are of low oncogenic potential [1-3]. Additional HPV types (including high oncogenic risk types) may be identified, but usually as co-infections with HPV 6 or 11.

For most patients, the presence of genital warts is concerning because of their cosmetic appearance, association with a sexually transmitted disease, bothersome symptoms, absence of a cure, and social stigma [4]. Although treatment can eradicate the warts, disease recurrence is common and occurs in 20 to 30 percent of patients overall.

This topic will discuss treatment of vulvar and vaginal warts in women. The epidemiology, pathophysiology, clinical manifestations, and diagnosis of anogenital warts, and issues related to men with anogenital infection, are reviewed separately. (See "Condylomata acuminata (anogenital warts) in adults: Epidemiology, pathogenesis, clinical features, and diagnosis" and "Condylomata acuminata (anogenital warts): Management of external condylomata acuminata in men".)


Patients should be given an explanation of their disease and information about the indications for treatment, treatment options, and prognosis. Written material is available from several sources (see 'Information for patients' below).  

Information about human papillomavirus infection — Most women want to know how and when they acquired the disease. We tell them that genital human papillomavirus (HPV) is spread by direct physical contact during sex. They may have acquired the infection years prior to diagnosis since the incubation period can last for months and their first recognition of a lesion may represent a relapse rather than a first episode. Therefore, a new diagnosis of genital warts does not mean that the patient or her partner is having sex outside the relationship. We also inform them that condoms provide some protection against HPV transmission, but contact with genital lesions not covered by the condom can result in infection [5].

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Sep 27, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Greer CE, Wheeler CM, Ladner MB, et al. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol 1995; 33:2058.
  2. Brown DR, Schroeder JM, Bryan JT, et al. Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. J Clin Microbiol 1999; 37:3316.
  3. Aubin F, Prétet JL, Jacquard AC, et al. Human papillomavirus genotype distribution in external acuminata condylomata: a Large French National Study (EDiTH IV). Clin Infect Dis 2008; 47:610.
  4. Steben M, LaBelle D. Genital warts: Canadians' perception, health-related behaviors, and treatment preferences. J Low Genit Tract Dis 2012; 16:409.
  5. Manhart LE, Koutsky LA. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis 2002; 29:725.
  6. Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64:1.
  7. Wiley DJ, Douglas J, Beutner K, et al. External genital warts: diagnosis, treatment, and prevention. Clin Infect Dis 2002; 35:S210.
  8. Lacey CJ, Woodhall SC, Wikstrom A, Ross J. 2012 European guideline for the management of anogenital warts. J Eur Acad Dermatol Venereol 2013; 27:e263.
  9. Schoenfeld A, Ziv E, Levavi H, et al. Laser versus loop electrosurgical excision in vulvar condyloma for eradication of subclinical reservoir demonstrated by assay for 2'5' oligosynthetase human papillomavirus. Gynecol Obstet Invest 1995; 40:46.
  10. Ferenczy A, Mitao M, Nagai N, et al. Latent papillomavirus and recurring genital warts. N Engl J Med 1985; 313:784.
  11. Stern PL, van der Burg SH, Hampson IN, et al. Therapy of human papillomavirus-related disease. Vaccine 2012; 30 Suppl 5:F71.
  12. Sycuro LK, Xi LF, Hughes JP, et al. Persistence of genital human papillomavirus infection in a long-term follow-up study of female university students. J Infect Dis 2008; 198:971.
  13. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists. Number 61, April 2005. Human papillomavirus. Obstet Gynecol 2005; 105:905.
  14. Bashi SA. Cryotherapy versus podophyllin in the treatment of genital warts. Int J Dermatol 1985; 24:535.
  15. A comparison of interferon alfa-2a and podophyllin in the treatment of primary condylomata acuminata. The Condylomata International Collaborative Study Group. Genitourin Med 1991; 67:394.
  16. Jensen SL. Comparison of podophyllin application with simple surgical excision in clearance and recurrence of perianal condylomata acuminata. Lancet 1985; 2:1146.
  17. Stone KM, Becker TM, Hadgu A, Kraus SJ. Treatment of external genital warts: a randomised clinical trial comparing podophyllin, cryotherapy, and electrodesiccation. Genitourin Med 1990; 66:16.
  18. Claesson U, Lassus A, Happonen H, et al. Topical treatment of venereal warts: a comparative open study of podophyllotoxin cream versus solution. Int J STD AIDS 1996; 7:429.
  19. Greenberg MD, Rutledge LH, Reid R, et al. A double-blind, randomized trial of 0.5% podofilox and placebo for the treatment of genital warts in women. Obstet Gynecol 1991; 77:735.
  20. Tyring S, Edwards L, Cherry LK, et al. Safety and efficacy of 0.5% podofilox gel in the treatment of anogenital warts. Arch Dermatol 1998; 134:33.
  21. Recurrent condylomata acuminata treated with recombinant interferon alpha-2a. A multicenter double-blind placebo-controlled clinical trial. Condylomata International Collaborative Study Group. Acta Derm Venereol 1993; 73:223.
  22. Yliskoski M, Saarikoski S, Syrjänen K, et al. Cryotherapy and CO2-laser vaporization in the treatment of cervical and vaginal human papillomavirus (HPV) infections. Acta Obstet Gynecol Scand 1989; 68:619.
  23. Gollock JM, Slatford K, Hunter JM. Scissor excision of anogenital warts. Br J Vener Dis 1982; 58:400.
  24. Khawaja HT. Treatment of condyloma acuminatum. Lancet 1986; 1:208.
  25. Calkins JW, Masterson BJ, Magrina JF, Capen CV. Management of condylomata acuminata with the carbon dioxide laser. Obstet Gynecol 1982; 59:105.
  26. Bellina JH. The use of the carbon dioxide laser in the management of condyloma acuminatum with eight-year follow-up. Am J Obstet Gynecol 1983; 147:375.
  27. Vance JC, Davis D. Interferon alpha-2b injections used as an adjuvant therapy to carbon dioxide laser vaporization of recalcitrant ano-genital condylomata acuminata. J Invest Dermatol 1990; 95:146S.
  28. Beutner KR, Reitano MV, Richwald GA, Wiley DJ. External genital warts: report of the American Medical Association Consensus Conference. AMA Expert Panel on External Genital Warts. Clin Infect Dis 1998; 27:796.
  29. Gunter J. Genital and perianal warts: new treatment opportunities for human papillomavirus infection. Am J Obstet Gynecol 2003; 189:S3.
  30. Bonnez W, Elswick RK Jr, Bailey-Farchione A, et al. Efficacy and safety of 0.5% podofilox solution in the treatment and suppression of anogenital warts. Am J Med 1994; 96:420.
  31. Abdullah AN, Walzman M, Wade A. Treatment of external genital warts comparing cryotherapy (liquid nitrogen) and trichloroacetic acid. Sex Transm Dis 1993; 20:344.
  32. Swinehart JM, Skinner RB, McCarty JM, et al. Development of intralesional therapy with fluorouracil/adrenaline injectable gel for management of condylomata acuminata: two phase II clinical studies. Genitourin Med 1997; 73:481.
  33. Heaton CL. Clinical manifestations and modern management of condylomata acuminata: a dermatologic perspective. Am J Obstet Gynecol 1995; 172:1344.
  34. Ferenczy A. Comparison of 5-fluorouracil and CO2 laser for treatment of vaginal condylomata. Obstet Gynecol 1984; 64:773.
  35. Krebs HB. Treatment of extensive vulvar condylomata acuminata with topical 5-fluorouracil. South Med J 1990; 83:761.
  36. Kirwan P, Naftalin NJ. Topical 5-fluorouracil in the treatment of vaginal intraepithelial neoplasia. Br J Obstet Gynaecol 1985; 92:287.
  37. Pride GL. Treatment of large lower genital tract condylomata acuminata with topical 5-fluorouracil. J Reprod Med 1990; 35:384.
  38. Krebs HB. Treatment of genital condylomata with topical 5-fluorouracil. Dermatol Clin 1991; 9:333.
  39. Tyring SK, Arany I, Stanley MA, et al. A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. J Infect Dis 1998; 178:551.
  40. Gotovtseva EP, Kapadia AS, Smolensky MH, Lairson DR. Optimal frequency of imiquimod (aldara) 5% cream for the treatment of external genital warts in immunocompetent adults: a meta-analysis. Sex Transm Dis 2008; 35:346.
  41. Garland SM, Waddell R, Mindel A, et al. An open-label phase II pilot study investigating the optimal duration of imiquimod 5% cream for the treatment of external genital warts in women. Int J STD AIDS 2006; 17:448.
  42. Edwards L, Ferenczy A, Eron L, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. Arch Dermatol 1998; 134:25.
  43. Beutner KR, Spruance SL, Hougham AJ, et al. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol 1998; 38:230.
  44. Meltzer SM, Monk BJ, Tewari KS. Green tea catechins for treatment of external genital warts. Am J Obstet Gynecol 2009; 200:233.e1.
  45. Drug Information: Veregen (kunecatechins). www.centerwatch.com/patient/drugs/dru938.html (Accessed on November 06, 2007).
  46. Veregen: a botanical for treatment of genital warts. Med Lett Drugs Ther 2008; 50:15.
  47. Tatti S, Swinehart JM, Thielert C, et al. Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial. Obstet Gynecol 2008; 111:1371.
  48. Stockfleth E, Beti H, Orasan R, et al. Topical Polyphenon E in the treatment of external genital and perianal warts: a randomized controlled trial. Br J Dermatol 2008; 158:1329.
  49. Eron LJ, Judson F, Tucker S, et al. Interferon therapy for condylomata acuminata. N Engl J Med 1986; 315:1059.
  50. Friedman-Kien AE, Eron LJ, Conant M, et al. Natural interferon alfa for treatment of condylomata acuminata. JAMA 1988; 259:533.
  51. Dinsmore W, Jordan J, O'Mahony C, et al. Recombinant human interferon-beta in the treatment of condylomata acuminata. Int J STD AIDS 1997; 8:622.
  52. Recurrent condylomata acuminata treated with recombinant interferon alfa-2a. A multicenter double-blind placebo-controlled clinical trial. Condylomata International Collaborative Study Group. JAMA 1991; 265:2684.
  53. Reichman RC, Oakes D, Bonnez W, et al. Treatment of condyloma acuminatum with three different interferon-alpha preparations administered parenterally: a double-blind, placebo-controlled trial. J Infect Dis 1990; 162:1270.
  54. Olmos L, Vilata J, Rodríguez Pichardo A, et al. Double-blind, randomized clinical trial on the effect of interferon-beta in the treatment of condylomata acuminata. Int J STD AIDS 1994; 5:182.
  55. Benedetti Panici P, Scambia G, Baiocchi G, et al. Randomized clinical trial comparing systemic interferon with diathermocoagulation in primary multiple and widespread anogenital condyloma. Obstet Gynecol 1989; 74:393.
  56. Keay S, Teng N, Eisenberg M, et al. Topical interferon for treating condyloma acuminata in women. J Infect Dis 1988; 158:934.
  57. Syed TA, Khayyami M, Kriz D, et al. Management of genital warts in women with human leukocyte interferon-alpha vs. podophyllotoxin in cream: a placebo-controlled, double-blind, comparative study. J Mol Med (Berl) 1995; 73:255.
  58. Cook K, Brownell I. Treatments for genital warts. J Drugs Dermatol 2008; 7:801.
  59. Böhle A, Büttner H, Jocham D. Primary treatment of condylomata acuminata with viable bacillus Calmette-Guerin. J Urol 2001; 165:834.
  60. Metawea B, El-Nashar AR, Kamel I, et al. Application of viable bacille Calmette-Guérin topically as a potential therapeutic modality in condylomata acuminata: a placebo-controlled study. Urology 2005; 65:247.
  61. Ting PT, Dytoc MT. Therapy of external anogenital warts and molluscum contagiosum: a literature review. Dermatol Ther 2004; 17:68.
  62. Baggish MS. Improved laser techniques for the elimination of genital and extragenital warts. Am J Obstet Gynecol 1985; 153:545.
  63. Baggish MS. Carbon dioxide laser treatment for condylomata acuminata venereal infections. Obstet Gynecol 1980; 55:711.
  64. Ferenczy A. Laser therapy of genital condylomata acuminata. Obstet Gynecol 1984; 63:703.
  65. Reid R, Greenberg MD, Pizzuti DJ, et al. Superficial laser vulvectomy. V. Surgical debulking is enhanced by adjuvant systemic interferon. Am J Obstet Gynecol 1992; 166:815.
  66. Ferenczy A, Bergeron C, Richart RM. Carbon dioxide laser energy disperses human papillomavirus deoxyribonucleic acid onto treatment fields. Am J Obstet Gynecol 1990; 163:1271.
  67. Rader JS, Leake JF, Dillon MB, Rosenshein NB. Ultrasonic surgical aspiration in the treatment of vulvar disease. Obstet Gynecol 1991; 77:573.
  68. Lacey CJ, Goodall RL, Tennvall GR, et al. Randomised controlled trial and economic evaluation of podophyllotoxin solution, podophyllotoxin cream, and podophyllin in the treatment of genital warts. Sex Transm Infect 2003; 79:270.
  69. Hellberg D, Svarrer T, Nilsson S, Valentin J. Self-treatment of female external genital warts with 0.5% podophyllotoxin cream (Condyline) vs weekly applications of 20% podophyllin solution. Int J STD AIDS 1995; 6:257.
  70. Fine P, Ball C, Pelta M, et al. Treatment of external genital warts at Planned Parenthood Federation of America centers. J Reprod Med 2007; 52:1090.
  71. Petersen CS, Bjerring P, Larsen J, et al. Systemic interferon alpha-2b increases the cure rate in laser treated patients with multiple persistent genital warts: a placebo-controlled study. Genitourin Med 1991; 67:99.
  72. Fleshner PR, Freilich MI. Adjuvant interferon for anal condyloma. A prospective, randomized trial. Dis Colon Rectum 1994; 37:1255.
  73. Armstrong DK, Maw RD, Dinsmore WW, et al. Combined therapy trial with interferon alpha-2a and ablative therapy in the treatment of anogenital warts. Genitourin Med 1996; 72:103.
  74. Douglas JM Jr, Eron LJ, Judson FN, et al. A randomized trial of combination therapy with intralesional interferon alpha 2b and podophyllin versus podophyllin alone for the therapy of anogenital warts. J Infect Dis 1990; 162:52.
  75. Armstrong DK, Maw RD, Dinsmore WW, et al. A randomised, double-blind, parallel group study to compare subcutaneous interferon alpha-2a plus podophyllin with placebo plus podophyllin in the treatment of primary condylomata acuminata. Genitourin Med 1994; 70:389.
  76. Handley JM, Horner T, Maw RD, et al. Subcutaneous interferon alpha 2a combined with cryotherapy vs cryotherapy alone in the treatment of primary anogenital warts: a randomised observer blind placebo controlled study. Genitourin Med 1991; 67:297.
  77. Rando RF, Lindheim S, Hasty L, et al. Increased frequency of detection of human papillomavirus deoxyribonucleic acid in exfoliated cervical cells during pregnancy. Am J Obstet Gynecol 1989; 161:50.
  78. Schneider A, Hotz M, Gissmann L. Increased prevalence of human papillomaviruses in the lower genital tract of pregnant women. Int J Cancer 1987; 40:198.
  79. Kemp EA, Hakenewerth AM, Laurent SL, et al. Human papillomavirus prevalence in pregnancy. Obstet Gynecol 1992; 79:649.
  80. Ciavattini A, Tsiroglou D, Vichi M, et al. Topical Imiquimod 5% cream therapy for external anogenital warts in pregnant women: report of four cases and review of the literature. J Matern Fetal Neonatal Med 2012; 25:873.
  81. Ferenczy A. HPV-associated lesions in pregnancy and their clinical implications. Clin Obstet Gynecol 1989; 32:191.
  82. Bergman A, Matsunaga J, Bhatia NN. Cervical cryotherapy for condylomata acuminata during pregnancy. Obstet Gynecol 1987; 69:47.
  83. Matsunaga J, Bergman A, Bhatia NN. Genital condylomata acuminata in pregnancy: effectiveness, safety and pregnancy outcome following cryotherapy. Br J Obstet Gynaecol 1987; 94:168.
  84. Ferenczy A. Treating genital condyloma during pregnancy with the carbon dioxide laser. Am J Obstet Gynecol 1984; 148:9.
  85. Schwartz DB, Greenberg MD, Daoud Y, Reid R. Genital condylomas in pregnancy: use of trichloroacetic acid and laser therapy. Am J Obstet Gynecol 1988; 158:1407.
  86. Adelson MD, Semo R, Baggish MS, Osborne NG. Laser vaporization of genital condylomata in pregnancy. J Gynecol Surg 1990; 6:257.
  87. Arena S, Marconi M, Frega A, Villani C. Pregnancy and condyloma. Evaluation about therapeutic effectiveness of laser CO2 on 115 pregnant women. Minerva Ginecol 2001; 53:389.
  88. Cook TA, Brunschwig JP, Butel JS, et al. Laryngeal papilloma: etiologic and therapeutic considerations. Ann Otol Rhinol Laryngol 1973; 82:649.
  89. Hallden C, Majmudar B. The relationship between juvenile laryngeal papillomatosis and maternal condylomata acuminata. J Reprod Med 1986; 31:804.
  90. Quick CA, Watts SL, Krzyzek RA, Faras AJ. Relationship between condylomata and laryngeal papillomata. Clinical and molecular virological evidence. Ann Otol Rhinol Laryngol 1980; 89:467.
  91. Niyibizi J, Rodier C, Wassef M, Trottier H. Risk factors for the development and severity of juvenile-onset recurrent respiratory papillomatosis: a systematic review. Int J Pediatr Otorhinolaryngol 2014; 78:186.
  92. Kashima HK, Shah K. Recurrent respiratory papillomatosis. Clinical overview and management principles. Obstet Gynecol Clin North Am 1987; 14:581.
  93. Silverberg MJ, Thorsen P, Lindeberg H, et al. Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis. Obstet Gynecol 2003; 101:645.
  94. Patsner B, Baker DA, Orr JW Jr. Human papillomavirus genital tract infections during pregnancy. Clin Obstet Gynecol 1990; 33:258.
  95. Shah KV. A case for immunization of human papillomavirus (HPV) 6/11-infected pregnant women with the quadrivalent HPV vaccine to prevent juvenile-onset laryngeal papilloma. J Infect Dis 2014; 209:1307.
  96. Sedlacek TV, Lindheim S, Eder C, et al. Mechanism for human papillomavirus transmission at birth. Am J Obstet Gynecol 1989; 161:55.
  97. Shah K, Kashima H, Polk BF, et al. Rarity of cesarean delivery in cases of juvenile-onset respiratory papillomatosis. Obstet Gynecol 1986; 68:795.
  98. Rogo KO, Nyansera PN. Congenital condylomata acuminata with meconium staining of amniotic fluid and fetal hydrocephalus: case report. East Afr Med J 1989; 66:411.
  99. Sarkola ME, Grénman SE, Rintala MA, et al. Human papillomavirus in the placenta and umbilical cord blood. Acta Obstet Gynecol Scand 2008; 87:1181.
  100. Chiasson MA, Ellerbrock TV, Bush TJ, et al. Increased prevalence of vulvovaginal condyloma and vulvar intraepithelial neoplasia in women infected with the human immunodeficiency virus. Obstet Gynecol 1997; 89:690.
  101. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997; 102:3.
  102. Gilson RJ, Shupack JL, Friedman-Kien AE, et al. A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients. Imiquimod Study Group. AIDS 1999; 13:2397.
  103. De Marco F, Di Carlo A, Poggiali F, et al. Detection of HPV in genital condylomata: correlation between viral load and clinical outcome. J Exp Clin Cancer Res 2001; 20:377.
  104. Massad LS, Xie X, Darragh T, et al. Genital warts and vulvar intraepithelial neoplasia: natural history and effects of treatment and human immunodeficiency virus infection. Obstet Gynecol 2011; 118:831.
  105. Kavanaugh BE, Odem-Davis K, Jaoko W, et al. Prevalence and correlates of genital warts in Kenyan female sex workers. Sex Transm Dis 2012; 39:902.
  106. Bryan JT, Stoler MH, Tyring SK, et al. High-grade dysplasia in genital warts from two patients infected with the human immunodeficiency virus. J Med Virol 1998; 54:69.
  107. Maniar KP, Ronnett BM, Vang R, Yemelyanova A. Coexisting high-grade vulvar intraepithelial neoplasia (VIN) and condyloma acuminatum: independent lesions due to different HPV types occurring in immunocompromised patients. Am J Surg Pathol 2013; 37:53.
  108. Conley LJ, Ellerbrock TV, Bush TJ, et al. HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet 2002; 359:108.
  109. Conant MA. Immunomodulatory therapy in the management of viral infections in patients with HIV infection. J Am Acad Dermatol 2000; 43:S27.
  110. Cusini M, Salmaso F, Zerboni R, et al. 5% Imiquimod cream for external anogenital warts in HIV-infected patients under HAART therapy. Int J STD AIDS 2004; 15:17.
  111. Saiag P, Bauhofer A, Bouscarat F, et al. Imiquimod 5% cream for external genital or perianal warts in human immunodeficiency virus-positive patients treated with highly active antiretroviral therapy: an open-label, noncomparative study. Br J Dermatol 2009; 161:904.
  112. Viazis N, Vlachogiannakos J, Vasiliadis K, et al. Earlier eradication of intra-anal warts with argon plasma coagulator combined with imiquimod cream compared with argon plasma coagulator alone: a prospective, randomized trial. Dis Colon Rectum 2007; 50:2173.
  113. Hogewoning CJ, Bleeker MC, van den Brule AJ, et al. Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. Int J Cancer 2003; 107:811.
  114. Bleeker MC, Berkhof J, Hogewoning CJ, et al. HPV type concordance in sexual couples determines the effect of condoms on regression of flat penile lesions. Br J Cancer 2005; 92:1388.
  115. Bleeker MC, Hogewoning CJ, Voorhorst FJ, et al. Condom use promotes regression of human papillomavirus-associated penile lesions in male sexual partners of women with cervical intraepithelial neoplasia. Int J Cancer 2003; 107:804.
  116. Blomberg M, Friis S, Munk C, et al. Genital warts and risk of cancer: a Danish study of nearly 50 000 patients with genital warts. J Infect Dis 2012; 205:1544.